Get the Stockscreener App
3.00
2.39%
0.07
After Hours:
3.00
Zentalis Pharmaceuticals Inc stock is traded at $3.00, with a volume of 1.78M.
It is up +2.39% in the last 24 hours and down -4.15% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
See More
Previous Close:
$2.93
Open:
$2.9
24h Volume:
1.78M
Relative Volume:
1.37
Market Cap:
$213.80M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.625
EPS:
-4.8
Net Cash Flow:
$-208.41M
1W Performance:
-2.91%
1M Performance:
-4.15%
6M Performance:
-42.86%
1Y Performance:
-77.88%
1-Day Range:
$2.89
$3.10
1-Week Range:
$2.795
$3.25
52-Week Range:
$2.66
$18.07
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
3.00 | 213.80M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
ZNTLZentalis Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Charles Schwab Investment Management Inc. Cuts Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Athersys (NASDAQ:ATHX) vs. Zentalis Pharmaceuticals (NASDAQ:ZNTL) Head to Head Review - Defense World
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm - Kilgore News Herald
Zentalis Pharmaceuticals expands leadership team - Investing.com India
Zentalis Pharmaceuticals Appoint Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer - citybiz
Zentalis Pharmaceuticals Announces Key Management Appointments - GlobeNewswire
Zentalis Pharmaceuticals Strengthens Leadership Team with Strategic Biotech Executive Appointments - StockTitan
The time has not yet come to remove your chips from the table: Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
Fmr LLC Has $18.68 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Osteosarcoma Market expected to rise | AlaMab Therapeutics, Zentalis Pharmaceuticals, Merck Eprova, Eisai Co Ltd., expected to drive Osteosarcoma market - Barchart
Osteosarcoma Market expected to rise | AlaMab Therapeutics, - openPR
Verition Fund Management LLC Buys 951,500 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Grants 4.5M Stock Options to New CEO, CMO & Employees | ZNTL Stock News - StockTitan
ZNTL (Zentalis Pharmaceuticals) EBITDA : $-207.96 Mil (TTM As of Sep. 2024) - GuruFocus.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - Defense World
Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $10.00 - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Sees Significant Drop in Short Interest - MarketBeat
Primecap Management Co. CA Boosts Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
What is HC Wainwright’s Forecast for ZNTL Q3 Earnings? - Defense World
Brokers Set Expectations for ZNTL Q3 Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for ZNTL FY2024 Earnings - MarketBeat
Guggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00 - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given Buy Rating at HC Wainwright - MarketBeat
Wedbush Has Positive Estimate for ZNTL FY2024 Earnings - MarketBeat
Citadel Advisors LLC Adjusts Stake in Zentalis Pharmaceuticals I - GuruFocus.com
ZNTL (Zentalis Pharmaceuticals) Enterprise Value : $282.73 Mil (As of Nov. 14, 2024) - GuruFocus.com
Zentalis Pharmaceuticals Announces New Leadership and Strategy Shift - TipRanks
Zentalis Pharmaceuticals Adds New Executives as Efforts Around Azenosertib Sharpen - MarketWatch
Zentalis Pharmaceuticals Announces Executive Leadership - GlobeNewswire
Zentalis Pharma Reshapes Leadership, Advances Cancer Drug Azenosertib Toward Key Trials | ZNTL Stock News - StockTitan
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Wealth Enhancement Advisory Services LLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
GSA Capital Partners LLP Purchases 353,384 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals Inc (ZNTL): Worth A Small Bite At $3.81 - Stocks Register
Eventide Asset Management's Strategic Reduction in Zentalis Phar - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Zentalis Pharmaceuti - GuruFocus.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World
Zentalis stock hits 52-week low at $2.82 amid market challenges - Investing.com Canada
Undervalued Opportunities: US Penny Stocks To Watch In October 2024 - Simply Wall St
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings - Yahoo Finance
Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - SETE News
Zentalis Pharmaceuticals Inc [ZNTL] Stock sold by Insider Vultaggio Vincent for $5098.0 - Knox Daily
Several Insiders Invested In Zentalis Pharmaceuticals Flagging Positive News - Yahoo Finance
Balance Sheet Insights: Zentalis Pharmaceuticals Inc (ZNTL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Zentalis Pharmaceuticals Inc (ZNTL)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Decreases By 26.2% - MarketBeat
ZNTL Shares Experience Decline in Value - Knox Daily
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.78 Consensus Price Target from Brokerages - MarketBeat
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vultaggio Vincent | Principal Accounting Officer |
Oct 04 '24 |
Sale |
3.18 |
1,603 |
5,098 |
33,855 |
| Gallagher Cam | President, Interim CFO |
May 31 '24 |
Sale |
11.98 |
9,597 |
114,972 |
633,680 |
| HAUSMAN DIANA | Chief Medical Officer |
May 09 '24 |
Sale |
12.62 |
3,356 |
42,353 |
373,876 |
| Epperly Melissa B, | Chief Financial Officer |
Feb 12 '24 |
Sale |
11.44 |
2,573 |
29,435 |
451,449 |
| Gallagher Cam | President |
Feb 12 '24 |
Sale |
11.44 |
1,173 |
13,419 |
643,277 |
| Lackner Mark | Chief Scientific Officer |
Feb 02 '24 |
Sale |
11.54 |
1,585 |
18,291 |
195,728 |
| Paul Andrea | Chief Legal Officer |
Feb 02 '24 |
Sale |
11.54 |
3,310 |
38,197 |
149,973 |
| Gallagher Cam | President |
Feb 02 '24 |
Sale |
11.54 |
11,552 |
133,310 |
644,450 |
| Epperly Melissa B, | Chief Financial Officer |
Feb 02 '24 |
Sale |
11.54 |
8,669 |
100,040 |
454,022 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):